Product image of Leuprone 3-Monatsdepot (Leuprorelin) supplied by GNH India

Leuprone 3-Monatsdepot

Active Ingredient:
Leuprorelin
Origin:
EU

Leuprone 3-Monatsdepot (Leuprorelin)

Leuprorelin, the active ingredient in Leuprone 3-Monatsdepot, is a GnRH agonist presented as a depot injection for subcutaneous use. It is used in the management of hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty and as adjuvant therapy in breast cancer.

GNH India supplies Leuprone 3-Monatsdepot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Hexal Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leuprorelin is employed in hormone‑dependent disease pathways to suppress sex hormone production.

  • Prostate cancer: reduces testosterone levels to slow tumor growth.
  • Endometriosis: lowers estrogen to alleviate pelvic pain and lesion progression.
  • Uterine fibroids: decreases estrogen to shrink fibroid size and reduce bleeding.
  • Precocious puberty: suppresses gonadotropin release to delay early sexual development.
  • Breast cancer (adjuvant therapy): lowers estrogen to reduce risk of recurrence.

How It Works

  • Leuprorelin is a synthetic analogue of gonadotropin‑releasing hormone (GnRH). After subcutaneous administration it initially stimulates pituitary GnRH receptors, causing a transient rise in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). Continuous exposure then desensitizes and down‑regulates these receptors, leading to markedly reduced secretion of LH and FSH, and consequently a profound decrease in gonadal production of testosterone and estrogen.

Side Effects

Leuprorelin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hot flashes: transient sweating and warmth.
  • Injection site reactions: pain, erythema or swelling.
  • Headache: mild to moderate intensity.
  • Fatigue: general tiredness.
  • Decreased libido: reduced sexual desire.

Serious or Rare Side Effects

  • Cardiovascular events: hypertension or thromboembolic episodes.
  • Bone mineral density loss: increased risk of osteoporosis.
  • Severe allergic reaction: anaphylaxis or angioedema.
  • Liver function abnormalities: elevated transaminases.
  • Pituitary apoplexy: rare hemorrhage within the gland.

Precautions & Warnings

When prescribing Leuprorelin, clinicians should consider several safety and handling precautions.

  • Cardiovascular assessment: evaluate history of hypertension, thromboembolism or heart disease.
  • Bone health monitoring: assess baseline bone mineral density and consider supplementation.
  • Hormone level checks: monitor testosterone or estrogen levels during therapy.
  • Diabetes management: watch for glucose intolerance or worsening diabetes.
  • Pregnancy and lactation: avoid use in women who are pregnant or may become pregnant; safety not established.
  • Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Avoid Interactions

Leuprorelin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Antidiabetic agents: may worsen glucose control; monitor blood sugar closely.
  • Hormone replacement therapy: concurrent estrogen or testosterone can counteract suppression.

Moderate Interactions (Monitor Closely)

  • CYP450 inhibitors/inducers: may alter metabolism of concomitant drugs.
  • Anticoagulants: potential increased bleeding risk due to hormonal effects.
  • Steroids: may affect bone density when combined with GnRH agonist.

Frequently Asked Questions

Leuprone 3-Monatsdepot, containing leuprorelin, is indicated for hormone‑dependent diseases such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and as adjuvant therapy in estrogen‑receptor positive breast cancer.

Leuprorelin is a synthetic GnRH agonist that initially stimulates, then continuously desensitizes pituitary GnRH receptors. This down‑regulation suppresses luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, leading to a marked reduction in testosterone and estrogen production, which slows the growth of hormone‑sensitive tissues.

The prescribing physician determines the exact dose and interval based on the patient’s condition. Leuprone 3-Monatsdepot is formulated as a three‑month depot injection that is administered subcutaneously at intervals specified by the treating clinician.

Safety of leuprorelin in pregnancy and lactation has not been established. The product is generally contraindicated in women who are pregnant, may become pregnant, or are breastfeeding, and alternative therapies should be considered.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Leuprone (leuprorelin) and goserelin belong to the same GnRH‑agonist class and share a similar mechanism of suppressing sex hormones. Differences lie mainly in formulation, dosing interval (Leuprone offers a three‑month depot) and specific regulatory approvals, allowing clinicians to select based on convenience, patient preference and therapeutic guidelines.

Leuprone 3-Monatsdepot should be stored at ambient temperature below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and avoid freezing the product.

The medication is given as a subcutaneous depot injection by a qualified healthcare professional. The injection is typically performed in the abdomen or thigh, and the formulation releases leuprorelin slowly over a three‑month period.

Serious adverse events include cardiovascular complications such as hypertension or thromboembolic events, significant loss of bone mineral density leading to osteoporosis, severe allergic reactions (anaphylaxis), liver enzyme elevations, and rare pituitary apoplexy. Patients should be monitored regularly for these conditions.

Leuprone is contraindicated in individuals with known hypersensitivity to leuprorelin or any excipients, pregnant or breastfeeding women, and patients with uncontrolled cardiovascular disease or severe osteoporosis without appropriate management. Clinicians should assess each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Leuprorelin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT